--- title: "Interventional Pancreatic APOLLO EA2192 | Sutter Health" description: "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation" url: "https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Interventional Pancreatic APOLLO EA2192 # Interventional Pancreatic APOLLO EA2192 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04858334). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. ![Ari D Baron, M.D.](https://dyn.mktgcdn.com/p/6yRtgxCIIRXiFOeBSBsWHHTovMS-k88mwc-hVtYQXNU/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Ari D Baron, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Interventional%20Pancreatic%20APOLLO%20EA2192%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Advanced Pancreatic Adenocarcinoma](https://www.sutterhealth.org/research/clinical-trials/adjuvant-advanced-pancreatic-adenocarcinoma-2075016358) Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma **Status:** Open to Enrollment - Clinical trial ### [Advanced or Metastatic Pancreatic Adenocarcinoma S2433](https://www.sutterhealth.org/research/clinical-trials/advanced-or-metastatic-pancreatic-adenocarcinoma-s2433-2051655936) Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma **Status:** Open to Enrollment - Clinical trial ### [Locally Advanced Pancreas Cancer GI011](https://www.sutterhealth.org/research/clinical-trials/locally-advanced-pancreas-cancer-gi011-2022195036) A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Interventional Pancreatic APOLLO EA2192"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#medicalwebpage","name":"Interventional Pancreatic APOLLO EA2192","description":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","url":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#breadcrumblist"},"mentions":[{"@type":"Person","name":"Ari D Baron, M.D.","url":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957#medicaltrial","name":"Interventional Pancreatic APOLLO EA2192","alternateName":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","url":"https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957","description":"This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.","identifier":"NCT04858334","code":{"@type":"MedicalCode","codeValue":"NCT04858334","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT04858334","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Pancreatic Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```